Why Your Body Destroys NAD+ Before It Can Use It (And the $5 Fix Nobody Talks About)

Your body cannot use NAD+ directly. The molecule is too large to pass through a cell membrane, so the moment you take an NAD+ supplement or receive an IV infusion, your body immediately breaks it back down into smaller components, ships those pieces inside the cell, and then rebuilds NAD+ from scratch on the inside. A 2019 study tracking IV NAD+ infusions found that 750 mg administered directly into the bloodstream was completely degraded before any of it reached the interior of a cell, with the breakdown products showing up in plasma and urine as confirmation that the whole thing got dismantled extracellularly.

That is not a flaw in the system. That is the system.

The process of reassembling NAD+ inside the cell is handled by something called the salvage pathway, which is essentially a recycling and rebuilding operation that takes the breakdown pieces of NAD+ and stitches them back together into usable fuel. NMN, NR, and NAD+ itself all feed into this same pathway, which means all three of those supplements are functionally converging on the same bottleneck.

The NMN situation is worth understanding specifically. A lot of marketing around NMN implies it enters cells directly and converts to NAD+ efficiently, but a 2016 study in Nature Communications identified that NMN cannot actually enter mammalian cells directly because the transporter that would carry it in is not present in most tissues. Instead, NMN gets converted to something called NR, which is nicotinamide riboside, before uptake occurs. So if you are taking NMN, your body is converting it to NR first, and then NR enters the cell, and then the salvage pathway finishes the job. NMN and NR are not two different routes. They are two different starting points on the same road.

Now here is where the age piece becomes important.

The salvage pathway slows down as you get older, not because the pathway itself breaks, but because of an enzyme called CD38 that becomes more active over time. CD38 is an NAD+ consuming enzyme and its job, roughly speaking, is to break down NAD+ as part of immune signaling. The problem is that CD38 activity increases somewhere between two and three fold across tissues with age, and a 2016 study found a near-perfect inverse relationship between CD38 activity and NAD+ levels, meaning the higher CD38 climbs, the lower NAD+ goes. More of the precursors you are taking are getting chewed up before the salvage pathway can do its work, which is why people over 40 or 50 often feel like NAD+ supplements are less effective than the research suggests they should be.

The salvage pathway is congested. And most NAD+ supplementation strategies are dumping more material into a congested system.

But the body has a second route entirely.

Something called the Preiss-Handler pathway takes a different form of vitamin B3, specifically nicotinic acid which is plain niacin, and converts it into NAD+ through a completely separate enzymatic sequence that does not run through the same bottleneck. The two pathways share an endpoint but not a road, so the traffic problem on the salvage pathway does not affect what happens via Preiss-Handler.

A 2020 study published in Cell Metabolism tested this directly in human patients with confirmed NAD+ deficiency caused by mitochondrial disease. Patients received niacin at 750 to 1000 milligrams per day, and after the supplementation period, blood NAD+ levels had increased 2.3 times and muscle NAD+ levels had increased 1.3 times. Alongside the NAD+ increases, the researchers also saw improvements in muscle strength and markers of mitochondrial biogenesis, which is the process of building new mitochondria.

For context, those NAD+ increases are in the same range as what studies report for NMN and NR supplementation at doses that cost $30 to $80 a month. Niacin at pharmacies runs roughly $5 a month.

There is one wrinkle worth understanding. Niacin produces something called a niacin flush, which is a temporary redness and warmth across the skin, particularly on the face, chest, and arms. It can feel alarming the first time it happens because it looks like an allergic reaction, but the mechanism is different. The flush is caused by niacin triggering the release of prostaglandins, which are signaling molecules that dilate small blood vessels near the skin surface. It is harmless and it typically diminishes significantly after the first two weeks of consistent use as the body adapts.

There is also an important distinction between niacin and niacinamide, which is another form of vitamin B3. Niacinamide does not cause the flush, which sounds convenient, but it also does not enter the Preiss-Handler pathway in the same way. Niacinamide feeds back into the salvage pathway, putting it in the same congested system as NMN and NR. If the goal is using the alternate route, the molecule that actually travels that route is niacin specifically.

One more piece that adds nuance to the picture. A 2019 study following NR supplementation in aged human skeletal muscle found something unexpected: a significant portion of the NR was showing up downstream as NAAD, which is an intermediate in the Preiss-Handler pathway, not the salvage pathway. This means that in practice, at least some NR converts to nicotinic acid in the body and re-enters via the Preiss-Handler route anyway. The pathways are not completely sealed off from each other in vivo. But the proportion that crosses over is not controlled, and it is not the primary route NR takes.

The practical question is straightforward. If your goal is raising NAD+ and you are under 35 with no specific deficiency, the salvage pathway is probably working well enough that NR or NMN may do the job. If you are older, or if you have noticed that NAD+ precursors seem to have a ceiling in your experience, or if you are simply looking for the lowest cost approach with direct clinical evidence, niacin at the doses used in that 2020 study is the version with the clearest data and the most direct pathway to the outcome.

The supplement industry built a category around one precursor, then a slightly different precursor, and each new molecule gets priced as if it is a breakthrough. But the body does not care which expensive precursor you chose. It cares whether NAD+ gets built inside the cell. And there has been a cheap, well-understood way to do that for decades that runs on completely different machinery.

---

References

1. Ratajczak J, Joffraud M, Trammell SAJ, et al. 2016. NRK1 controls nicotinamide mononucleotide and nicotinamide riboside metabolism in mammalian cells. Nature Communications, 7:13103. Finding: NMN must be converted to NR by CD73 before cellular uptake, establishing NR as the common entry point for both NMN and NR supplementation. Source
2. Elhassan YS, Kluckova K, Fletcher RS, et al. 2019. Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Cell Reports, 287:1717-1728. Finding: NR supplementation produced significant increases in NAAD a Preiss-Handler pathway intermediate in human muscle, indicating NR partially converts to nicotinic acid in vivo. Source
3. Pirinen E, Auranen M, Khan NA, et al. 2020. Niacin cures systemic NAD+ deficiency and improves muscle performance in adult-onset mitochondrial myopathy. Cell Metabolism, 316:1078-1090. Finding: Niacin 750-1000 mg/day raised blood NAD+ 2.3x and muscle NAD+ 1.3x in human subjects via the Preiss-Handler pathway, with concurrent improvements in muscle strength and mitochondrial biogenesis. Source
4. Grant R, Berg J, Mestayer R, et al. 2019. A pilot study investigating changes in the human plasma and urine NAD+ metabolome during a 6 hour intravenous infusion of NAD+. Frontiers in Aging Neuroscience, 11:257. Finding: IV NAD+ 750 mg was rapidly and completely removed from plasma, with metabolites confirming full extracellular degradation before cellular uptake. Source
5. Camacho-Pereira J, Tarrago MG, Chini CCS, et al. 2016. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metabolism, 236:1127-1139. Finding: CD38 activity increases 2-3 fold with age across tissues, with near-perfect inverse correlation to NAD+ levels. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness